2022-074 – Antibodies Against Orthohantaviruses


A hantavirus is a virus that is spread primarily by rodents and can cause varied disease syndromes in people worldwide. Hantaviruses identified in the Americas have been known as “New World” hantaviruses, while those in Europe and Asia are referred to as “Old World” hantaviruses. These viruses can cause health-related issues, such as hantavirus cardiopulmonary syndrome (HCPS) and hemorrhagic fever with renal syndrome (HFRS) respectively, both of which are known to have a high mortality rate. According to the CDC, there are currently no FDA-approved or emergency use-authorized vaccines or therapeutics available to treat hantavirus infections. The most common treatment plan for patients diagnosed early is to undergo oxygen therapy and to be intubated as hantavirus causes severe respiratory stress. The longer the patient waits to undergo medical care, the less likely the treatment plan is to be effective at treating the virus. Thus, there is a gap in the preparedness for a public health emergency caused by a potential outbreak, resulting in the need to identify and develop countermeasures and treatment options for those affected by hantaviruses.

Technology Description

Researchers have developed an antibody-based therapeutic to reduce the infection of hantaviruses. The method uses neutralizing antibodies to block the virus from entering the cell, thus reducing the potential for infection. These antibodies have demonstrated their effectiveness by blocking specific dissociation prior to viral membrane fusion target membrane insertion, and/or post-fusion homotorizerization. Depending on virus structure, the antibodies are capable of targeting both the “Old World” and the “New World” hantavirus. The newly developed broad neutralizing antibodies are beneficial in protecting against divergent hantaviruses. In addition, they are also useful for clinical development as a broad countermeasure against hantavirus infections such as cardiopulmonary syndrome (HCPS) and hemorrhagic fever with renal syndrome (HFRS).


  • Protects against divergent hantaviruses
  • Reduces the infection of hantaviruses
  • Useful in clinical development as a countermeasure against hantavirus infections
  • Useful in decreasing mortality rates
  • Therapeutic antibodies for the treatment of viral infections

Potential Applications

  • Hantavirus infections
  • “New World” hantavirus
  • “Old World” hantavirus

Contact Information

Name: Gregg Banninger

Email: GBanninger@innovations.unm.edu

Phone: 505-272-7908